Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Oct;68(10):669-678.
doi: 10.1369/0022155420960250. Epub 2020 Sep 14.

Phosphorylated Alpha-Synuclein Within Cutaneous Autonomic Nerves of Patients With Parkinson's Disease: The Implications of Sample Thickness on Results

Affiliations

Phosphorylated Alpha-Synuclein Within Cutaneous Autonomic Nerves of Patients With Parkinson's Disease: The Implications of Sample Thickness on Results

Ningshan Wang et al. J Histochem Cytochem. 2020 Oct.

Abstract

The detection of cutaneous phosphorylated alpha-synuclein (P-syn) in patients with Parkinson's disease (PD) has ranged from 30% to 100% across different studies. We hypothesize that part of the variability in P-syn detection is due to methodological differences using sections of different tissue thickness. Three skin biopsies were obtained from 29 individuals with PD and 21 controls. Tissues were cut into 10-, 20-, and 50-µm-thick sections and double-stained with protein gene product (PGP) 9.5 and P-syn. We quantified the deposition of P-syn with and without PGP 9.5 in sweat glands, pilomotor muscle, and blood vessels using confocal digital images of autonomic structures. Overall, the P-syn-positive rates with PGP 9.5 colocalization in subjects with PD were 100% using 50 µm sections, 90% using 20 µm sections, and 73% using 10 µm sections with 100% specificity. (No P-syn was detected within control subjects.) Without PGP 9.5, colocalization of the P-syn-positive rates was 100% for all samples, but specificity dropped below 70%. In this study, double-immunostained 50 µm skin biopsy tissue sections are superior to 20 and 10 µm tissue sections at detecting P-syn in subjects with PD. The increased sensitivity is likely secondary to a combination of greater volume of tissue analyzed and improved visualization of nerve fiber architecture.

Keywords: Parkinson’s disease; autonomic nerve system; phosphorylated alpha-synuclein-s129; skin biopsy.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Orthogonal Z-stack images of tissue sections with nerve fibers containing phosphorylated alpha-synuclein (P-syn) in individuals with Parkinson’s disease. Four examples of tissue sections are shown: two examples of 50 µm thickness, one example of 20 µm thickness, and one example of 10 µm thickness (displayed on the left Y-axis). The immunostains used for each image are shown on the top of the figure and included protein gene product 9.5 (PGP 9.5), P-syn, and the merged images. Sections A–C and G–I show pilomotor nerve fibers, and sections D–F are a nerve bundle. Sections J–L contain both pilomotor nerve fibers and nerve bundles. Thicker tissue sections tend to allow for easier identification of overlapping PGP 9.5 and P-syn. Scale bar, 100 μm.
Figure 2.
Figure 2.
Examples of phosphorylated alpha-synuclein (P-syn) artifacts. In this 50-µm-thick tissue section, a nerve bundle is stained with P-syn (seen in red in (A)) and protein gene product 9.5 (PGP 9.5 in green) with the merged orthogonal image shown in (B). The white arrows indicate regions of possible P-syn deposition in red. In the merged image, the regions do not colocalize with PGP 9.5. Without colocalization, it is easy to misinterpret artifacts for actual alpha-synuclein staining.

References

    1. Beach TG, Adler CH, Lue L, Sue LI, Bachalakuri J, Henry-Watson J, Sasse J, Boyer S, Shirohi S, Brooks R, Eschbacher J, White CL, III, Akiyama H, Caviness J, Shill HA, Connor DJ, Sabbagh MN, Walker DG. Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction. Acta Neuropathol. 2009;117(6):613–634. doi:10.1007/s00401-009-0538-8 - DOI - PMC - PubMed
    1. Yamasaki TR, Holmes BB, Furman JL, Dhavale DD, Su BW, Song ES, Cairns NJ, Kotzbauer PT, Diamond MI. Parkinson’s disease and multiple system atrophy have distinct alpha-synuclein seed characteristics. J Biol Chem. 2019;294(3):1045–1058. doi:10.1074/jbc.RA118.004471 - DOI - PMC - PubMed
    1. Koga S, Aoki N, Uitti RJ, van Gerpen JA, Cheshire WP, Josephs KA, Wszolek ZK, Langston JW, Dickson DW. When DLB, PD, and PSP masquerade as MSA: an autopsy study of 134 patients. Neurology. 2015;85(5):404–412. doi:10.1212/WNL.0000000000001807. - DOI - PMC - PubMed
    1. Beach TG, Adler CH, Sue LI, Vedders L, Lue L, White CL, III, Akiyama H, Caviness JN, Shill HA, Sabbagh MN, Walker DG. Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders. Acta Neuropathol. 2010;119(6):689–702. doi:10.1007/s00401-010-0664-3 - DOI - PMC - PubMed
    1. Caviness JN, Lue LF, Beach TG, Hentz JG, Adler CH, Sue L, Sadeghi R, Driver-Dunckley E, Evidente VG, Sabbagh MN, Shill HA, Walker DG. Parkinson’s disease, cortical dysfunction, and alpha-synuclein. Mov Disord. 2011;26:1436–1442. doi:10.1002/mds.23697 - DOI - PMC - PubMed

Substances